Patient died during Hanmi Pharma's lung cancer drug candidate's clinical trial
Sept 30, 2016
[THE INVESTOR] Hanmi Pharmaceutical 's novel lung cancer therapy candidate HM61713 was found to have side effects of serious skin toxicity during the second phase of clinical trial carried out in collaboration with Boehringer Ingelheim, according to the Ministry of Food and Drug Safety on Sept. 30. At least one patient has died during the clinical trial due to severe skin adverse reactions.The pharmaceutical composition showed inspiring therapeutic efficacy in the first phase of clinical trial c